LINTA Pharmaceuticals

What LINTA Pharmaceuticals does

LINTA Pharmaceuticals is a Pakistan-based pharmaceutical manufacturer founded in 2012 and headquartered at the National Industrial Zone in Rawat, Islamabad. The company manufactures and supplies generic pharmaceutical products across six dosage forms — tablets, capsules, dry powder suspensions, creams, gels, ointments, and injectables — covering therapeutic categories that include anti-cancer (Letrozole, Anastrozole), anti-anginal, antibiotics (cephalosporins, fluoroquinolones, macrolides, carbapenems), anesthetics, analgesics, cardiovascular, central nervous system, gastrointestinal, and dermatological products. The portfolio comprises 215+ registered products marketed under multiple brand names, with the company operating from a single manufacturing facility employing 501-1,000 staff.

The company runs a four-stage manufacturing process covering formulation development, production and process control, quality control and testing, and packaging and labeling. An R&D center has been established in collaboration with leading academic institutions to identify and develop compounds with therapeutic potential. The company is led by CEO Muhammad Faheem Qureshi and claims publicly traded status on its investor page, although no stock ticker or exchange listing is disclosed.

LINTA generates revenue through one-time sales of pharmaceutical products distributed primarily via a distributor network reaching hospitals, clinics, and pharmacies in Pakistan, supplemented by direct inquiry channels for bulk and enterprise orders. The company states a reach of 84,000+ patients. No public pricing model, revenue figure, or customer concentration disclosure is available, and operating geographies are confirmed only for Pakistan within South Asia, despite aspirational language about global patient accessibility.

Name

LINTA Pharmaceuticals

Legal name

LINTA Pharmaceuticals Private Limited

Website

https://lintapharmaceuticals.com

Company type

Public

Founded year

2012

Operating status

Operating

Headcount range

501–1,000 employees

Short description

LINTA Pharmaceuticals is a Pakistan-based generic drug manufacturer founded in 2012, producing tablets, capsules, dry suspensions, creams, ointments, and injectables across 215+ registered products spanning oncology, cardiovascular, antibiotics, CNS, and dermatology, sold primarily through domestic distributor networks.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (42421), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Drugs and Druggists' Sundries Merchant Wholesalers (4242)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Medicinal Chemicals & Botanical Products (2833), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Respiratory & Allergy Pharmaceuticals (HLAIAAAH), Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Generic pharmaceutical manufacturing
• Finished dosage formulations
• Sterile injectable products
• Topical dermatological products
• Antibiotic and analgesic production

Headquarters

HQ city

Islamabad

HQ country

Pakistan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Revenue generated through manufacturing and supplying pharmaceutical products including prescription medications, over-the-counter products, and specialized treatments across therapeutic categories including anti-cancer, anti-anginal, antibiotics, anesthetics, and analgesics. Products are sold through distributor networks to healthcare providers and patients.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

LINTA Pharmaceuticals manufactures and supplies a broad portfolio of generic finished pharmaceutical products in five dosage forms — tablets, capsules, dry powder suspensions, creams/ointments, and sterile injectables. Its 215+ registered products cover therapeutic categories such as anti-cancer, anti-anginal, antibiotics, anesthetics, analgesics, antidepressants, antiepileptics, antihistamines, cardiovascular agents, antimalarials, anticoagulants, proton pump inhibitors, NSAIDs, statins, and dermatologicals, sold under brand names such as Pyras, Tril-P, Hicox, Rifarex, Soivan, Critam, Zota, Pari, Lintazip, Lot, Atovas, and Ravixben.

Product overview

LINTA Pharmaceuticals is a pharmaceutical company manufacturing and supplying a comprehensive portfolio of generic pharmaceutical products. The product portfolio spans multiple therapeutic categories organized across six core dosage forms: Tablets (including controlled-release formulations), Capsules (including pellets), Dry Powder Suspensions, Creams and Gels, Ointments, and Injectable solutions. Key therapeutic areas include Anti-Cancer medications (Letrozole, Anastrozole), Anti-Anginal drugs (Glyceryl trinitrate), Antibiotics (Ciprofloxacin, Levofloxacin, Azithromycin, Cefixime, Meropenem, Ceftriaxone), Anesthetic/Analgesics (various NSAIDs, Tramadol combinations), Psychiatric/CNS drugs (Sertraline, Escitalopram, Pregabalin, Duloxetine), Cardiovascular medications (Amlodipine combinations, Beta-blockers, Statins, Anticoagulants), Gastrointestinal drugs (Proton pump inhibitors, Itopride), and Dermatological products (Topical antifungals, corticosteroids, acne treatments). The products are marketed under various brand names including Pyras, Tril-P, Hicox, Rifarex, Soivan, Critam, Ozamide, Zota, Pari, Lintazip, Lot, Atovas, Ravixben, and many others, targeting healthcare providers and patients in Pakistan and internationally.

Differentiator

Problem solved

Functional benefit

Products and services

• Tablets Oral solid dosage form pharmaceutical products including analgesics, antibiotics, cardiovascular medications, CNS drugs, gastrointestinal treatments, and combination products in tablet form, covering brands such as Pyras, Tril-P, Hicox, Rifarex, Oflamic, Azonic, Ithromycin, Siprion, Alflox, Gim, M-Nidazole, Ketovit, Soinsil, Esiclin, Fimcic, Fimra, Mistra, Zota, Citopam, Pari, Ozlin, GD-MET, S-Met, Soivan, Oldif, Betahist, Opi-Gril, Critam, Ozamide, Topima, Lamegin, Deslin, Finda, L-Rdin, Kislin, C-Terazin, Amther, Mirvan, Ravixben, Candexil, Vincent, Lot-H Plus, Lot, Abenda, Lintazip, Relnom, Itza, Soliten, Ldura, Tizyl, Elopamat, Sitelol, Atelol, Prozase, Carvipress, Biwa, Ampoline, Zetia, Karvodin, Lefulin, FMT, Monwell, Hary-P, Lintofin, Dapofin, Aldigesic, Lintosid, Clofzam, Clof SR, Lofan, Melonex, Lexopren, Vicam, Glitric, Phynocit, Sevla, Rabin/Kamrib, Resitam, Atovas, RTS, Pavilot, Audinet, Orphenda-Fort, Pnol, Nate D, Lintcob, Tragnit, Fabix, and Algoric.
• Capsules Encapsulated pharmaceutical products including antibiotics, proton pump inhibitors, psychiatric medications, anti-inflammatory drugs, and specialty pellet-based and extended-release formulations, covering brands such as Blin, Logigab, Velo, Osef, Zixpro, Zinta, Ompalin, Makzo, Vosta, Macthio, Alfatam, Irox, Extam, Pioxi, Revibra, Lintalox, Linteflox, Lintazip-F, Psyfax-SR, Ritoderm, Fletzil, Martidox, Fenolin, and Mogplus.
• Dry Powder Suspensions Reconstituted dry powder suspension formulations of antibiotics including Cefixime, Cefpodoxime, Cefadroxil, and Cephradine in pediatric and adult strengths, sold under the brands Zixpro Dry Suspensions, Orid Dry Suspensions, Osef Suspensions, and Velo 250mg Dry Susp.
• Creams and Ointments Topical pharmaceutical formulations including antifungals, corticosteroids, antibiotics, anti-inflammatory gels, and dermatological treatments for conditions such as acne, eczema, psoriasis, pigmentation disorders, burns, and wounds, covering brands such as CTM-V, Kenozyl, Mizonase-V, Aktalin-V, Aktalin Oral Gel, CTM 1% Cream, Iscona-D, Zihyd-Plus, Soinsil 1.0% Cream, Clof Gel, Ketpro Gel, Pioxi Gel, Fude, Fude-H, Acutin Gel, Acutin-E Gel, Acpro Gel, Clin Gel, Melalite Cream, Betso, Betso-N, Betso-G, Climcin, Bzoyl, Meslone Cream, Meslone Ointment, Sifo-Derm, Pionate-F, Rolinta Ointment, Zylaic, and Xylocain Ointment.
• Injections Sterile injectable pharmaceutical products for IV/IM administration in hospital and clinical settings, including Ceftriaxone Sodium (CT-X Injections in 250mg, 500mg, and 1gm), Meropenem (Merinta Injections in 500mg and 1gm), and Cefoperazone Sodium with Sulbactam Sodium combination (Lintasul Injections).

Quantifiable outcome

• 84,000+ patients served
• +1 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Leading Academic InstitutionscoreStrategic or Co-development PartnerLinta Pharmaceuticals has established a cutting-edge R&D Center in collaboration with leading academic institutions. This partnership allows the company to leverage the expertise of renowned scientists and scholars, ensuring that research is at the forefront of innovation for developing compounds with significant therapeutic potential.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Hilton Pharma: Pakistan-based pharmaceutical company with a multi-category branded-generics portfolio. Similar in size tier, distribution model, and therapeutic breadth.
• The Searle Company: Major Pakistani pharmaceutical company with a diversified branded-generics and specialty portfolio. Closely comparable in business model, geographic focus, and product breadth.
• Highnoon Laboratories: Pakistani pharmaceutical manufacturer with broad therapeutic coverage including cardiovascular, anti-infectives, and CNS. Comparable in scale, generics focus, and Pakistan-market orientation.
• Sami Pharmaceuticals: Pakistani specialty and generic pharmaceutical manufacturer with diverse therapeutic categories. Comparable as a domestic Pakistan pharma peer with similar go-to-market model.
• AGP Limited: Pakistani pharmaceutical manufacturer with broad generic portfolio and established hospital and retail presence. Directly comparable in business model and product mix.
• Getz Pharma: One of Pakistan's largest domestic pharmaceutical manufacturers with a broad generic and specialty portfolio across multiple therapeutic areas. Directly comparable to LINTA as a Pakistan-headquartered generic manufacturer serving hospitals, clinics, and retail pharmacies.

Broad incumbents

• GlaxoSmithKline Pakistan: Multinational pharmaceutical incumbent with established Pakistan operations across prescription, OTC, and vaccines. Comparable in therapeutic breadth but materially larger scale and brand equity.
• Sanofi Pakistan: Multinational pharmaceutical company with Pakistan operations covering specialty and primary care. Overlaps with LINTA in cardiovascular, diabetes, and CNS but operates at greater scale and with proprietary products.
• Abbott Laboratories (Pakistan): Multinational pharmaceutical company operating in Pakistan with broad therapeutic coverage and a branded-generics portfolio. Larger and broader than LINTA but overlapping in product categories and channels.

Regional players

• Brookes Pharma: Pakistan-based pharmaceutical manufacturer with generics portfolio focused on antibiotics, anti-malarials, and primary care categories. Comparable in size and domestic focus to LINTA, with potential overlap in anti-infective therapy areas.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

• Facebookfacebook.com/profile.php?id=XXXXXXXX
• Xx.com/linta_ppl
• YouTubeyoutube.com/channel/XXXXXXXX
• Pinterestpinterest.com/XXXXXXXX

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LINTA Pharmaceuticals